Citrulline
|
Basic information |
| Metabolite name | Citrulline |
 | HMDB0000904 |
 |
C00327 |
 |
9750 |
| Synonyms | L-Citrulline |
| No. of studies | 27 |
|
Basic information |
| Metabolite name | Citrulline |
| HMDB0000904 |
|
C00327 |
|
9750 |
| Synonyms | L-Citrulline |
| No. of studies | 27 |
|
Relationship between Citrulline and depression (count: 27) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M050 | Type3 | 2h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1076 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M1095 | Type1 | CUMS group vs. control group | Faece | ICR mouse | Up |
| Study M1095 | Type2 | CUMS + matrine group vs. CUMS group | Faece | ICR mouse | Down |
| Study M111 | Type3 | WT-Scop group vs. WT-Veh group | Plasma | C57BL/6 mouse | Down |
| Study M112 | Type5 | paroxetine-treated responder group vs. non-responder group | Hippocampus | DBA/2J mouse | Down |
| Study M1135 | Type2 | PSD + electroacupuncture group vs. PSD group | Faece | Sprague-Dawley rat | Up |
| Study M472 | Type3 | S-Ket group vs. control group | PC12 cell | Rat | Down |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M639 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M647 | Type1 | antepartum depression group vs. control group | Plasma | Human | Down |
| Study M693 | Type1 | SDS group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M712 | Type1 | depression group vs. control group | Liver | Cynomolgus monkey | Down |
| Study M739 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M739 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M756 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M779 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M885 | Type1 | CMS-vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M972 | Type1 | CRS + irradiation group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M972 | Type2 | CRS + irradiation + paeoniflorin group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M972 | Type2 | CRS + irradiation + albiflorin group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M972 | Type2 | CRS + irradiation + Paeoniae Radix Alba group vs. CRS + irradiation group | Serum | Sprague-Dawley rat | Up |
| Study M981 | Type2 | Abeta oligomer + involuntary and voluntary running + acousto-optic stimulation group vs. Abeta oligomer group | Serum | ICR mouse | Down |